Comparative Pharmacology
Head-to-head clinical analysis: ALORA versus DELESTROGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALORA versus DELESTROGEN.
ALORA vs DELESTROGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol binds to estrogen receptors (ERα and ERβ), activating gene transcription and non-genomic signaling pathways, resulting in proliferation of endometrial tissue.
Estradiol, the active component, binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene transcription and exerting estrogenic effects on the reproductive, cardiovascular, skeletal, and central nervous systems.
Estradiol (ALORA) transdermal patch: 0.025-0.1 mg/day applied twice weekly. Typical starting dose 0.05 mg/day.
10-20 mg intramuscularly every 4 weeks for estrogen replacement therapy.
None Documented
None Documented
The terminal elimination half-life of estradiol is approximately 13-19 hours following transdermal administration, reflecting slow release from the skin depot and ongoing metabolism. This half-life allows for continuous hormone levels with once- or twice-weekly dosing.
Terminal elimination half-life: ~12-24 hours; clinical context: prolonged with hepatic impairment, steady-state achieved within ~5-7 days of daily IM dosing
Alora (estradiol transdermal system) is eliminated primarily via hepatic metabolism, with approximately 60% of a dose excreted in urine as glucuronide and sulfate conjugates, and about 40% excreted in feces via biliary elimination.
Renal (primarily as glucuronide and sulfate conjugates, ~50-80%), fecal (~10-20%)
Category C
Category C
Estrogen
Estrogen